STOCK TITAN

PACB (PACB) officer Mark Van Oene sells 184,897 shares, partly for taxes

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. officer Mark Van Oene reported two transactions in the company’s common stock. On February 17, 2026, he sold 129,790 shares in open-market transactions at a weighted average price of $1.576 per share, with individual prices ranging from $1.55 to $1.70. On February 18, 2026, he sold 55,107 shares at a weighted average price of $1.629 per share, with prices ranging from $1.51 to $1.68. The filing states that the reported amount includes shares mandatorily sold to cover tax withholding obligations upon vesting of restricted stock units. After these transactions, he directly owned 1,742,638 shares, which includes 7,500 shares acquired on September 2, 2025 under the company’s 2010 Employee Stock Purchase Plan.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Van Oene Mark

(Last) (First) (Middle)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.,
1305 O'BRIEN DRIVE

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/17/2026 S 129,790(1) D $1.576(2) 1,797,745(3) D
Common Stock 02/18/2026 S 55,107(1) D $1.629(4) 1,742,638(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares mandatorily sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
2. This sale price represents the weighted average sale price of the shares sold ranging from $1.51 to $1.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. Includes 7,500 shares purchased on September 2, 2025 under the Company's 2010 Employee Stock Purchase Plan.
4. This sale price represents the weighted average sale price of the shares sold ranging from $1.55 to $1.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Remarks:
Chief Operating Officer
/s/ Michele Farmer, Attorney-in-fact 02/19/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PACB officer Mark Van Oene report in this Form 4?

He reported selling 184,897 shares of PACB common stock across two days. The sales occurred in open-market transactions on February 17 and 18, 2026, at weighted average prices of $1.576 and $1.629 per share, respectively.

Were any of Mark Van Oene’s PACB share sales related to tax withholding?

Yes. The filing notes that a portion of the reported shares was mandatorily sold to cover tax withholding obligations tied to the vesting of restricted stock units. This means some sales were for tax purposes rather than discretionary portfolio changes.

What prices did Mark Van Oene receive for his PACB share sales?

The reported weighted average prices were $1.576 per share on February 17, 2026, and $1.629 per share on February 18, 2026. Individual sale prices ranged from $1.55 to $1.70 and $1.51 to $1.68, respectively.

How many PACB shares does Mark Van Oene hold after these transactions?

Following the reported sales, Mark Van Oene directly owned 1,742,638 shares of PACB common stock. This figure includes 7,500 shares that were purchased on September 2, 2025 under the company’s 2010 Employee Stock Purchase Plan.

What type of ownership does Mark Van Oene report for his PACB shares?

The filing classifies his holdings as direct ownership of PACB common stock. There is no indication in the provided data of indirect ownership through entities such as trusts, partnerships, or family investment vehicles for the reported transactions.

How many total PACB shares did Mark Van Oene sell in this Form 4 period?

Across the two reported days, he sold a total of 184,897 shares of PACB common stock. These transactions are categorized as open-market sales, with some shares sold specifically to satisfy tax withholding obligations tied to restricted stock unit vesting.

Pacific Biosc

NASDAQ:PACB

PACB Rankings

PACB Latest News

PACB Latest SEC Filings

PACB Stock Data

507.20M
274.44M
Medical Devices
Laboratory Analytical Instruments
Link
United States
MENLO PARK